TY - JOUR
T1 - Safety and immunogenicity of an AMA1 malaria vaccine in Malian children
T2 - Results of a phase 1 randomized controlled trial
AU - Thera, Mahamadou A.
AU - Doumbo, Ogobara K.
AU - Coulibaly, Drissa
AU - Laurens, Matthew B.
AU - Kone, Abdoulaye K.
AU - Guindo, Ando B.
AU - Traore, Karim
AU - Sissoko, Mady
AU - Diallo, Dapa A.
AU - Diarra, Issa
AU - Kouriba, Bourema
AU - Daou, Modibo
AU - Dolo, Amagana
AU - Baby, Mounirou
AU - Sissoko, Mahamadou S.
AU - Sagara, Issaka
AU - Niangaly, Amadou
AU - Traore, Idrissa
AU - Olotu, Ally
AU - Godeaux, Olivier
AU - Leach, Amanda
AU - Dubois, Marie Claude
AU - Ballou, W. Ripley
AU - Cohen, Joe
AU - Thompson, Darby
AU - Dube, Tina
AU - Soisson, Lorraine
AU - Diggs, Carter L.
AU - Takala, Shannon L.
AU - Lyke, Kirsten E.
AU - House, Brent
AU - Lanar, David E.
AU - Dutta, Sheetij
AU - Heppner, D. Gray
AU - Plowe, Christopher V.
PY - 2010
Y1 - 2010
N2 - Background: The objective was to evaluate the safety and immunogenicity of the AMA1-based malaria vaccine FMP2.1/AS02A in children exposed to seasonal falciparum malaria. Methodology/Principal Findings: A Phase 1 double blind randomized controlled dose escalation trial was conducted in Bandiagara, Mali, West Africa, a rural town with intense seasonal transmission of Plasmodium falciparum malaria. The malaria vaccine FMP2.1/AS02A is a recombinant protein (FMP2.1) based on apical membrane antigen 1 (AMA1) from the 3D7 clone of P. falciparum, formulated in the Adjuvant System AS02A. The comparator vaccine was a cell-culture rabies virus vaccine (RabAvert®). One hundred healthy Malian children aged 1-6 years were recruited into 3 cohorts and randomized to receive either 10 μg FMP2.1 in 0.1 mL AS02A, or 25 μg FMP2.1 in 0.25 mL AS02A, or 50 μg FMP2.1 50 μg in 0.5 mL AS02A, or rabies vaccine. Three doses of vaccine were given at 0, 1 and 2 months, and children were followed for 1 year. Solicited symptoms were assessed for 7 days and unsolicited symptoms for 30 days after each vaccination. Serious adverse events were assessed throughout the study. Transient local pain and swelling were common and more frequent in all malaria vaccine dosage groups than in the comparator group, but were acceptable to parents of participants. Levels of anti-AMA1 antibodies measured by ELISA increased significantly (at least 100-fold compared to baseline) in all 3 malaria vaccine groups, and remained high during the year of follow up. Conclusion/Significance:The FMP2.1/AS02A vaccine had a good safety profile, was well-tolerated, and induced high and sustained antibody levels in malaria-exposed children. This malaria vaccine is being evaluated in a Phase 2 efficacy trial in children at this site. Trial Registration: ClinicalTrials.gov NCT00358332 [http://clinicaltrials.gov/ ct2/show/NCT00358332].
AB - Background: The objective was to evaluate the safety and immunogenicity of the AMA1-based malaria vaccine FMP2.1/AS02A in children exposed to seasonal falciparum malaria. Methodology/Principal Findings: A Phase 1 double blind randomized controlled dose escalation trial was conducted in Bandiagara, Mali, West Africa, a rural town with intense seasonal transmission of Plasmodium falciparum malaria. The malaria vaccine FMP2.1/AS02A is a recombinant protein (FMP2.1) based on apical membrane antigen 1 (AMA1) from the 3D7 clone of P. falciparum, formulated in the Adjuvant System AS02A. The comparator vaccine was a cell-culture rabies virus vaccine (RabAvert®). One hundred healthy Malian children aged 1-6 years were recruited into 3 cohorts and randomized to receive either 10 μg FMP2.1 in 0.1 mL AS02A, or 25 μg FMP2.1 in 0.25 mL AS02A, or 50 μg FMP2.1 50 μg in 0.5 mL AS02A, or rabies vaccine. Three doses of vaccine were given at 0, 1 and 2 months, and children were followed for 1 year. Solicited symptoms were assessed for 7 days and unsolicited symptoms for 30 days after each vaccination. Serious adverse events were assessed throughout the study. Transient local pain and swelling were common and more frequent in all malaria vaccine dosage groups than in the comparator group, but were acceptable to parents of participants. Levels of anti-AMA1 antibodies measured by ELISA increased significantly (at least 100-fold compared to baseline) in all 3 malaria vaccine groups, and remained high during the year of follow up. Conclusion/Significance:The FMP2.1/AS02A vaccine had a good safety profile, was well-tolerated, and induced high and sustained antibody levels in malaria-exposed children. This malaria vaccine is being evaluated in a Phase 2 efficacy trial in children at this site. Trial Registration: ClinicalTrials.gov NCT00358332 [http://clinicaltrials.gov/ ct2/show/NCT00358332].
UR - http://www.scopus.com/inward/record.url?scp=77649084917&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0009041
DO - 10.1371/journal.pone.0009041
M3 - Article
C2 - 20140214
SN - 1932-6203
VL - 5
SP - 1
EP - 11
JO - PLoS One
JF - PLoS One
IS - 2
M1 - e9041
ER -